Five-Year Reactivation After Ranibizumab or Aflibercept Treatment for Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy

To evaluate 5-year reactivation after ranibizumab or aflibercept treatment for neovascular age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). This retrospective study included 192 patients (192 eyes) who had been diagnosed with neovascular AMD or PCV and treated with...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of ocular pharmacology and therapeutics 2021-11, Vol.37 (9), p.525-533
Hauptverfasser:	Kim, Jae Hui, Kim, Jong Woo, Kim, Chul Gu
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Factors Aged Aged, 80 and over Angiogenesis Inhibitors - therapeutic use Choroidal Neovascularization - drug therapy Choroidal Neovascularization - pathology Comorbidity Female Humans Macular Degeneration - drug therapy Macular Degeneration - pathology Male Middle Aged Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - therapeutic use Retrospective Studies Sex Factors Visual Acuity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!